| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a protected amino acid derivative, H-D-Tyr-OMe.HCl does not have a specific pharmacological target. Its primary role is as a chemical building block in peptide synthesis. Upon deprotection, D-tyrosine may interact with tyrosinase, amino acid transporters, and D-amino acid oxidase. D-tyrosine has been shown to inhibit tyrosinase activity and biofilm formation.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies have shown that D-tyrosine derivatives inhibit tyrosinase activity and reduce melanin synthesis. Research has demonstrated that D-tyrosine effectively inhibits biofilm formation in various bacterial species. Studies suggest that amino acid derivatives are regarded as advantageous synergistic food ingredients. |
| ln Vivo |
In vivo studies on D-tyrosine derivatives are limited. D-tyrosine has been studied for its potential effects on melanin synthesis and biofilm formation in animal models. However, H-D-Tyr-OMe.HCl specifically has limited published in vivo data.
|
| Enzyme Assay |
In vitro tyrosinase inhibition assays typically use mushroom tyrosinase with L-DOPA as substrate. For biofilm inhibition assays, bacterial cultures are grown with varying concentrations of the compound.
|
| Cell Assay |
In vitro cellular assays for D-tyrosine derivatives typically employ melanocyte cell lines. Cells are treated with varying concentrations of the compound and melanin content is measured.
|
| Animal Protocol |
In vivo animal studies with D-tyrosine derivatives typically utilize mouse models. The compound is administered orally or via intraperitoneal injection.
|
| ADME/Pharmacokinetics |
H-D-Tyr-OMe.HCl (molecular weight 231.68 g/mol) is a small molecule with moderate lipophilicity. The methyl ester is susceptible to hydrolysis. Following absorption, the compound undergoes ester hydrolysis and normal tyrosine metabolism.
|
| Toxicity/Toxicokinetics |
The hydrochloride salt of H-D-Tyr-OMe exhibits low toxicity. Acute toxicity is expected to be low.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
H-D-Tyr-OMe.HCl is supplied as a white to off-white solid with ≥98% purity. The product is for research use only and is not approved for human therapeutic applications.
|
| Molecular Formula |
C6H14CLNO2
|
|---|---|
| Molecular Weight |
167.6339
|
| Exact Mass |
167.071
|
| CAS # |
5619-05-6
|
| PubChem CID |
12498813
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
145.7ºC at 760 mmHg
|
| Melting Point |
171ºC
|
| Flash Point |
20.7ºC
|
| LogP |
1.645
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
10
|
| Complexity |
101
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl[H].O(C([H])([H])[H])C(C([H])(C([H])(C([H])([H])[H])C([H])([H])[H])N([H])[H])=O
|
| InChi Key |
KUGLDBMQKZTXPW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H13NO2.ClH/c1-4(2)5(7)6(8)9-3;/h4-5H,7H2,1-3H3;1H
|
| Chemical Name |
methyl 2-amino-3-methylbutanoate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9655 mL | 29.8276 mL | 59.6552 mL | |
| 5 mM | 1.1931 mL | 5.9655 mL | 11.9310 mL | |
| 10 mM | 0.5966 mL | 2.9828 mL | 5.9655 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
